00:00And it is my pleasure to welcome in the CEO of Kamada Pharmaceuticals, Amir London.
00:08It's fantastic to be with you today, Amir.
00:12Thank you, Dan.
00:12Thank you for having me.
00:14The pleasure and honor is all mine.
00:15Well, let's just start off here and give everyone an overview of your company, if you want.
00:19Yes, absolutely.
00:21Kamada is a publicly traded commercial stage biopharmaceutical company focused on a specialty
00:27plasma-derived product, a very unique biopharmaceutical field of activity.
00:33We are global leaders in that field with six FDA-approved products.
00:37Everything we do is life-saving therapeutics.
00:41We are vertically integrated from plasma collection through R&D development, clinical trials,
00:47production, all the way to commercializing our products in over 35 countries across the globe.
00:54That's amazing stuff.
00:55And let's dive a little deeper, Amir.
00:57What are plasma-derived therapeutics?
00:59And why is this approach especially powerful?
01:02Okay.
01:03Thank you very much.
01:04So plasma-derived therapeutics are basically products, therapeutics, drugs, which are made
01:09from human plasma.
01:11So we collect human plasma in plasma collection centers, mainly based in the U.S.
01:16We have the ability to collect plasma from people that have high titer, high antibody level
01:22against specific viruses.
01:23We know how to quantify the potency of those antibodies.
01:30And we know how to purify them into drugs, into pharmaceuticals that are used in all kinds
01:35of acute cases.
01:37I'll give maybe just two examples.
01:38One product called KEDRAB, or outside of the U.S., CAMRAB, which is anti-rabis hemoglobulin,
01:44which means anti-rabis antibodies for people that were exposed to potentially rabid animal, which
01:50is a deadly disease.
01:51The second type of product is our cytogun, which is an anti-CMV.
01:56CMV is a type of virus which is the number one reason for rejection or failure of solid
02:03organ transplantation.
02:05Patients that are exposed to this virus may lose their new organ.
02:09And we give them a boost of those specific antibodies as part of the procedure.
02:14So these are really acute cases, you know, acute care, transplantation, very unique products.
02:25And we've developed a significant know-how.
02:27We've been around for 35 years.
02:29We've been public on NASDAQ since 2013.
02:33And we're making great progress in our unique field of activity.
02:38Now, it's absolutely fascinating stuff.
02:40And I know, Amir, you had a positive year on report.
02:42Revenue was up 13% year over year.
02:45What were the main drivers of this growth, as well as your 2025 guidance?
02:48And what will contribute to this year's growth?
02:51Excellent.
02:51So, yes, we had a very good year.
02:542024 was a record year for Kamada.
02:55By the way, just yesterday, on the 7th, so two days ago,
03:00it was the first time that we actually paid dividend based on the very strong results of 2024.
03:06Yeah, it's good to be a CEO of a company that had just paid dividend for the first time.
03:10I'm sure that the shareholders like me today.
03:14In any case, yeah, we had a very strong year.
03:17We've grown based on multiple products.
03:20We opened plasma collection centers.
03:21We grew significantly our anti-revis product in the U.S. market.
03:25From a $32 million in the year prior to $50 million sales in 2024.
03:31We've grown our CytoGum, the CMV product, which I mentioned earlier, from $17 million to around $23 million.
03:39So this was a very good year for us in terms of significant growth drivers.
03:43Moving between 2024 to 2025, I'm happy to say that we're basically growing in all our lines of business, in all products.
03:52So it's a really well-balanced growth, not just focused on one product, one territory, but across multiple pillars of growth that we have.
04:00And we guided the market, we'll be selling in 2025 between $178 to $182 million, with EBITDA between $38 to $42 million.
04:12We're running at around 22%, 23% of EBITDA from top line.
04:16We've been improving our bottom line and top line every year, double digits, in the last few years.
04:22And we've improved the rate of EBITDA from top line, which means that we are growing in a very profitable way.
04:29Those are great numbers.
04:30And listen, they always love you as CEO, Amer, but definitely love you even more when there's a dividend.
04:34So that's great stuff.
04:36I know you mentioned your target to expand commercial operations through M&A.
04:40Could you elaborate on what types of M&A you're looking to secure right now?
04:43Yeah, so we're trying, of course, to look for target opportunities, and we're screening for opportunities in areas as synergetic as possible to our current business.
04:54So we are, as I mentioned, a commercial stage.
04:56We have products all in the U.S.
04:57We have our commercial team focused on plasma-derived and transplantation centers.
05:03We're covering all major transplants in the U.S.
05:06We're looking even broader than that.
05:08You know, we have activities also in the Middle East where we have our own commercial team distributing our products.
05:14So it's an area of multiple areas that we're looking at, and we're very optimistic that we'll be able to execute at least one transaction in licensing or M&A this year.
05:25We finished the year with over $78 million, and we plan that this money will mainly be used in order to accelerate the growth through acquisitions.
05:34Of course. And I know you also, you've expanded your plasma collection capabilities.
05:39What is the strategic goal around this activity?
05:42Right. So we are opening plasma collection centers.
05:44We opened one in Houston in September of last year, just recently opened another one in San Antonio.
05:49These are very large, automated, highly advanced plasma centers.
05:54We focus on specialty plasma for our needs, anti-rabies, anti-epithitis, anti-D,
06:00and we're also using the balance capacity in each one of those centers to collect what's called normal source plasma, regular plasma,
06:06which is being used basically for other purposes, making more like generic type of immunoglobulins.
06:12And this is something that we're going to sell out to our external partners.
06:16So it's both being more vertically integrated, more independent, reducing our cost of goods,
06:20and being able to increase our top line by selling plasma to external partners.
06:26That's fantastic. And I wanted to get you to tell me a little bit about your lead product that hailed AAT and what the next milestone is.
06:34Correct. So this is a lead product in development.
06:36So as I said, we have six FDA-approved products.
06:38We have multiple clinical programs.
06:41The most advanced one is a next-generation investigational treatment for a disease called alpha-ondeficiency.
06:47We are selling through an agreement with Takeda in the U.S., the kind of third-generation product, which is an IV treatment, infused treatment.
06:56We will be able, using our advanced technology, to also develop it as an inhaled, nebulized, non-invasive treatment done by patients at home without need to go to the clinic.
07:07It's in the middle of the phase three study.
07:09The next milestone will be towards the end of this year.
07:11We're going to have an interim data based on statistical analysis that we're going to do using an external kind of unblinded committee,
07:21which is going to look into our – have a peek into our data and give us feedback on the data-to-date.
07:29Yes. So this will be by the end of the year.
07:31As mentioned, we are on midway into the phase three pivotal study.
07:36This area is already around $1.2, $1.3 billion, growing significantly.
07:42We expect that if we are successful in the current study and we bring the product to the market, we will be a major player in the $2 billion market.
07:49So this can be a really very nice add-on to our existing growing business.
07:53I love it.
07:54Very exciting times that come out of pharmaceuticals.
07:56Listen, it was an absolute pleasure talking with you, Amir.
07:58Thank you so much for your time.
08:00Thank you very much, Dan, and good luck.
08:02Bye-bye.